A multinational phase III study of PLX-PAD to improve recovery following surgery for femoral neck fracture

Trial Profile

A multinational phase III study of PLX-PAD to improve recovery following surgery for femoral neck fracture

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Muscle injury
  • Focus Registrational; Therapeutic Use
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 26 Sep 2017 According to a Pluristem Therapeutics media release, the company plans to submit the Investigational New Drug (IND) and Clinical Trial Application (CTA) for the trial in the coming months. The company plans to use results of trial to achieve marketing approval in both the U.S. and Europe.
    • 26 Sep 2017 According to a Pluristem Therapeutics media release, the company has received a positive feedback on the proposed study design and endpoints of the trial from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA).
    • 05 Sep 2017 According to a Pluristem Therapeutics media release, this trial will be a collaborative effort between Pluristem and an international consortium led by the Charite Universitatsmedizin Berlin, under the leadership of Dr Tobias Winkler.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top